The estimated Net Worth of Sumit Aggarwal is at least $167 dollars as of 1 December 2021. Mr Aggarwal owns over 279,158 units of Eloxx Pharmaceuticals Inc stock worth over $167 and over the last 4 years he sold ELOX stock worth over $0.
Mr has made over 1 trades of the Eloxx Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 279,158 units of ELOX stock worth $167 on 1 December 2021.
The largest trade he's ever made was exercising 279,158 units of Eloxx Pharmaceuticals Inc stock on 1 December 2021 worth over $167. On average, Mr trades about 55,832 units every 0 days since 2021. As of 1 December 2021 he still owns at least 279,158 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Mr Aggarwal stock trades at the bottom of the page.
Sumit Aggarwal M.B.A. is the Pres, CEO & Director at Eloxx Pharmaceuticals Inc.
Mr A is 48, he's been the Pres y CEO & Director of Eloxx Pharmaceuticals Inc since . There are 9 older and 2 younger executives at Eloxx Pharmaceuticals Inc. The oldest executive at Eloxx Pharmaceuticals Inc is Zafrira Avnur, 68, who is the Independent Director.
Sumit's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, SUITE 130, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv y Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: